ÂÜÀòÂÒÂ×

Mark O'Dair, PhD, serves as a Principal Scientist at Allogene Therapeutics since January 2022, following a comprehensive academic and research career. Prior experience includes roles at the University of California, Berkeley, where Mark was a Research Specialist and Graduate Student Researcher, focusing on the biophysical study of early immune T cell signaling. Mark's teaching experience as a Graduate Student Instructor involved leading large classes and small discussion groups. Additionally, Mark held the position of Funding Officer at the Graduate Assembly at UC Berkeley, managing a grant portfolio of $200K. Earlier research at the University of Utah involved the development of novel catalysts and targeted mutagenesis in various labs. Mark O'Dair's academic credentials include a PhD in Physical Chemistry from UC Berkeley and a BS in Chemistry from the University of Utah.